Article Cited by others


Bone-targeted therapies to reduce skeletal morbidity in prostate cancer

Dorff Tanya B, Agarwal Neeraj

Year : 2018| Volume: 20| Issue : 3 | Page no: 215-220

   This article has been cited by
1 A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population
Sushil K. Badrising,Rebecca D. Louhanepessy,Vincent Noort,Jules L.L.M. Coenen,Paul Hamberg,Aart Beeker,Nils Wagenaar,Marnix G.E.H. Lam,Filiz Celik,Olaf J.L. Loosveld,Ad Oostdijk,Hanneke Zuetenhorst,John B. Haanen,Erik Vegt,Wilbert Zwart,Andries M. Bergman
International Journal of Cancer. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Pharmacogenomics of osteonecrosis of the jaw
Guang Yang,Sonal Singh,Yiqing Chen,Issam S. Hamadeh,Taimour Langaee,Caitrin W. McDonough,L. Shannon Holliday,Jatinder K. Lamba,Jan S. Moreb,Joseph Katz,Yan Gong
Bone. 2019; 124: 75
[Pubmed]  [Google Scholar] [DOI]
3 Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin
Yongzhong Wei,Mina Elahy,Anna M. Friedhuber,Jia Y. Wong,Jeffery D. Hughes,Michael R. Doschak,Crispin R. Dass
Bone. 2019; 124: 103
[Pubmed]  [Google Scholar] [DOI]
4 Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Juan Gómez Rivas,Diego M. Carrion,Mario Alvarez-Maestro,Xavier Cathelineau,Rafael Sanchez-Salas,Giuseppe Di Lorenzo,Massimo Di Maio,Asit Paul,Luis Martinez-Piñeiro,Oliver Sartor,Fred Saad,Francis Debruyne
Minerva Urologica e Nefrologica. 2019; 71(5)
[Pubmed]  [Google Scholar] [DOI]


Read this article